Pradaxa onto PBS
August 6, 2013
Boehringer Ingelheim
has confirmed that Pradaxa
(dabigatran) will be PBS listed from
01 September for the prevention
of stroke and systemic embolism
in patients with non-valvular
atrial fibrillation and at least one
additional risk factor for stroke.
The move comes more than
two and a half years after the
Pharmaceutical Benefits Advisory
Committee first recommended
the PBS listing of Pradaxa, with
BI md for Australia and NZ, Wes
Cook, saying it is “great news that
Australians with atrial fibrillation
will finally have affordable access to
this important therapy”.
“Boehringer Ingelheim would like
to thank those doctors who cared
for the 25,000 patients who have
received Pradaxa at no cost through
the company’s access program over
the last two years,” he said.
BI will continue to support
patients until 01 Sep, after which
they will be able to fill their scripts
at the standard PBS co-payment
through community pharmacies.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Aug 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Aug 13
